The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1609
ISSUE 1609
October 19, 2020
Issue 1609
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Timing of Remdesivir for COVID-19
October 19, 2020 (Issue: 1609)
Remdesivir (Veklury – Gilead), an investigational
antiviral drug administered by IV infusion, is now
available through an FDA Emergency Use Authorization
(EUA) for treatment of COVID-19 in all hospitalized
patients. An earlier EUA limited use of the drug to
patients hospitalized with severe disease.
... more
- COVID-19 update: FDA broadens emergency use authorization for Veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. FDA 2020 August 28. Available at: https://bit.ly/3hUs7fO. Accessed October 8, 2020.
- JH Beigel et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020 October 8 (epub).
- CD Spinner et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324:1048.
- CDC. Duration of isolation and precautions for adults with COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Accessed October 8, 2020.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1609
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian